Pfizer's Cibinqo snags FDA approval to challenge Sanofi and Regeneron's Dupixent in eczema

Look out, Sanofi and Regeneron: Pfizer is on the scene in atopic dermatitis with another blockbuster-to-be.

Friday, the FDA approved the New York drugmaker's oral daily JAK1 inhibitor Cibinqo to treat adults with moderate to severe atopic dermatitis who have not been able to get their disease under control with other medicines including biologics and for those who can't take other treatments.